Halozyme Therapeutics (HALO) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • 11/02/21
Why the Earnings Surprise Streak Could Continue for Halozyme Therapeutics (HALO)Zacks Investment Research • 10/28/21
Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference CallPRNewsWire • 10/19/21
SA Interview: Investing In The Pharmaceutical Industry With Small Pharma AnalystSeeking Alpha • 10/16/21
Halozyme Therapeutics (HALO) Up 4.2% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/08/21
Halozyme Stock Gains As Q2 Earnings Top Estimates On Higher Milestone, Royalty; Lifts FY21 GuidanceBenzinga • 08/10/21
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Halozyme To Host Second Quarter 2021 Financial Results Webcast and Conference CallPRNewsWire • 07/27/21
Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent RelapsePRNewsWire • 07/12/21
Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple MyelomaPRNewsWire • 06/22/21
GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme DealBenzinga • 06/22/21
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIVBusiness Wire • 06/22/21
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIVPRNewsWire • 06/22/21